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Because hyper-excitability has been shown to be a shared pathophysiological mechanism, we used the
latest and largest genome-wide studies in amyotrophic lateral sclerosis (n ¼ 36,052) and epilepsy (n ¼
38,349) to determine genetic overlap between these conditions. First, we showed no significant ge-
netic correlation, also when binned on minor allele frequency. Second, we confirmed the absence of
polygenic overlap using genomic risk score analysis. Finally, we did not identify pleiotropic variants in
meta-analyses of the 2 diseases. Our findings indicate that amyotrophic lateral sclerosis and epilepsy
do not share common genetic risk, showing that hyper-excitability in both disorders has distinct
origins.
 2020 The Author(s). Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
Amyotrophic lateral sclerosis (ALS) is characterized by the pro-
gressive degeneration of motor neurons. Cramps and fasciculations
are common in ALS patients and indicate axonal hyper-excitability
in motor neurons (Kanai et al., 2006). Proposed mechanisms for
hyper-excitability in ALS include impaired inhibitory signaling
through GABAergic interneurons, astrocytes failing to adequately
regulate glutamate levels and extracellular Kþ concentrations at
the synaptic cleft, and altered ion channel expression in motorGWAS Consortium and the
Complex Epilepsies) is pro-
y Material.
ogy and Neurosurgery, Uni-
5500, 3508GA Utrecht, the
5 554 94.
ldink).
er Inc. This is an open access articlneurons (Do-Ha et al., 2018). Ion channel dysfunction has been
correlated to muscle weakness and motor neuron degeneration
(Geevasinga et al., 2015), while peripheral hyper-excitability and
central hyper-excitability are furthermore strong predictors of
shorter survival (Kanai et al., 2012; Shimizu et al., 2018). Similarly,
in epilepsy, an imbalance of excitatory and inhibitory mechanisms
in the brain contributes to seizure pathogenesis. Interestingly, the
anti-epileptic drug retigabine has shown acute beneficial effects on
peripheral nerve excitability in ALS (Kovalchuk et al., 2018). Of
further note, riluzoleda drug used in the treatment of ALSdhas
been shown to decrease hippocampal epileptiform activity and
reduce seizure activity in epilepsy animal models (Diao et al., 2013;
Kim et al., 2007).
The beforementioned observations and the availability of recent
and large genome-wide association study (GWAS) datasets (The
International League Against Epilepsy Consortium on Complex
Epilepsies, 2018; van Rheenen et al., 2016), showing that the heri-
tability of each of the 2 diseases is partly explained by common
genetic variation, have led us to investigate whether ALS and epi-
lepsy share any common genetic risk.e under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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We used individual level data of subjects with European
ancestry from recent large GWASs in ALS (N ¼ 12,577 cases; 23,475
controls) (van Rheenen et al., 2016) and epilepsy (N ¼ 14,131 cases;
24,218 controls), including sets of focal (n ¼ 9095 cases) and
generalized (n ¼ 3305 cases) epilepsy subtypes (The International
League Against Epilepsy Consortium on Complex Epilepsies,
2018). We then performed genetic correlation analyses, genomic
risk score (GRS) analyses, and meta-analyses (Supplementary
Methods).
3. Core data
We found no significant genetic correlations between ALS and
epilepsy, including focal and generalized subtypes (Fig. 1).
Furthermore, genetic risk for epilepsy was not associated with
caseecontrol status in the ALS dataset (Fig. 2A, Supplementary
Table 3A), and similarly ALS GRSs did not associate with epilepsy
status (Fig. 2B, Supplementary Table 3B). Inverse-varianceweighted
meta-analyses of ALS and epilepsy revealed several loci passing the
threshold for genome-wide significance (Fig. 3, Supplementary
Figs. 2 and 3, Supplementary Table 4). Only the locus near BMP8A
in the ALS-epilepsy (all subtypes combined) analysis (Fig. 3A) ful-
filled criteria for a pleiotropic locus with nominal-significant as-
sociation p-values (p < 0.05) in both studies independently (ALS,
p ¼ 2.3  102; epilepsy, p ¼ 8.7  108) and a genome-wide sig-
nificant p-value in meta-analysis (p ¼ 3.2  108, odds ratio ¼ 1.02,
similar effect directions). This variant, however, was not associated
with ALS (p ¼ 0.11) in a larger GWAS for which only summary
statistics were available (Nicolas et al., 2018).
4. Discussion
We have used the latest and largest individual-level genotype
datasets for ALS and epilepsy to perform the most comprehensive
cross-disorder genome-wide study between these diseases avail-
able to date. This has enabled careful control of sample overlap and
relatedness between datasets. Also, many tools for cross-disorder
analyses have increased power because they use individual-level
genotype data instead of summary statistics. Moreover, the ge-
netic correlation estimate between these disorders was not re-
ported in a recent large-scale study on shared polygenic risk in ALSFig. 1. Genetic correlation between ALS and epilepsy. Genetic correlation between ALS and e
SNPs in the MAF range 0.01e0.5 (GCTA-All) and on SNPs in 5 MAF bins and using GCTA-GR
Error bars indicate 95% confidence intervals. Abbreviations: ALS, amyotrophic lateral sclero
likelihood; LD, linkage disequilibrium; LDSC, linkage disequilibrium score regression; MAF,(Bandres Ciga et al., 2019). Overall, we showed with the currently
available sample sizes that ALS and epilepsy are not genetically
correlated, and that GRS capturing combined effects of common
variants in one disease do not explain phenotypic variance in the
other disease and that no loci with an effect in both ALS and epi-
lepsy were identified in meta-analyses.
The loci near BMP8A and PTPRK initially showed evidence for
pleiotropy, because of their nominal significant association in both
ALS and epilepsy GWAS and stronger statistical association in the
meta-analysis and sign-independent meta-analysis, respectively.
Nevertheless, the associations of top single-nucleotide poly-
morphisms (SNPs) in these loci with ALS were weak and did not
reach nominal significance in a more recent and larger ALS GWAS
meta-analysis (Nicolas et al., 2018), which combined logistic
regression association results from summary-level data of van
Rheenen et al. (2016) and individual-level data of additional co-
horts. Although the meta-analysis framework applied in that larger
study could be less powerful compared to a mixed linear model
approach with full individual-level data, we were unable prove
pleiotropy for these loci. Since only summary statistics of that larger
ALS GWAS meta-analysis were available, we were furthermore
unable to perform all our analyses including those data. Moreover,
the contribution of epilepsy to the pleiotropic signals was large
with association p-values around the genome-wide significance
threshold (The International League Against Epilepsy Consortium
on Complex Epilepsies, 2018). These results do not support the
notion that these loci are associated with both diseases.
Our results find support in epidemiological data reporting an
absence of comorbidity between ALS and epilepsy (Tartaglia et al.,
2007), although case reports of co-occurrence in C9orf72 repeat
expansion carriers exist (Capasso et al., 2016; Janssen et al., 2016;
van den Ameele et al., 2018). Detailed C9orf72 repeat expansion
status was currently unavailable in our ALS dataset. Although
several sodium and potassium channel genes have been associated
with epilepsy, and involvement of these channels in the develop-
ment of cramps in ALS has been proposed (Helbig et al., 2008; Kanai
et al., 2006; The International League Against Epilepsy Consortium
on Complex Epilepsies, 2018), our results suggest that these clinical
observations are not a consequence of shared polygenic architec-
ture. Cramps in ALSmight thus be a consequence of disease-specific
pathology leading to a hyper-excitable state of motor neurons, for
which anti-epileptic drugs can still be effective (Kovalchuk et al.,
2018).pilepsy (including focal and generalized subtypes) (y-axis) was estimated based on all
EML (x-axis). Furthermore, LDSC was used to estimate genetic correlation (All-LDSC).
sis; GCTA, Genome-wide Complex Trait Analysis; GREML, genetic restricted maximum
minor allele frequency; SNP, single-nucleotide polymorphism.
A
B
Fig. 2. GRS analysis results. Twelve GRSs were calculated per individual in the target dataset and tested for association with the target disease using logistic regression (x-axis). (A)
Epilepsy GWAS results were used as discovery datasets, and ALS was used as the target dataset. (B) ALS GWAS results were used as the discovery dataset, and epilepsy and subtypes
were used as target datasets. Odds ratios reflect the amount by which the odds of ALS (in A) or epilepsy (in B) changes per SD increase in GRS (all GRS were scaled around mean
0 with SD 1). Error bars indicate 95% confidence intervals. The p-value threshold for significant GRS association was Bonferroni-corrected for 6 analyses times 12 PT (p <
6.94  104). Detailed results are shown in Supplementary Table 3. Abbreviations: ALS, amyotrophic lateral sclerosis; GRS, genomic risk score; GWAS, genome-wide association
study; SD, standard deviation.
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cannot rule out that a study with even larger datasets may possibly
yield significant results. However, such a correlation would then be
expected to be very small, as we have shown no sign of substantial
shared genetic risk with the current large GWAS datasets we have
analyzed. The current sample size provides 80% power to detect a
genetic correlation of 0.091 at a ¼ 0.05 using GCTA-REML (Visscher
et al., 2014). Second, rare genetic variation plays a role in both dis-
eases. Although we found non-significant genetic correlation esti-
mates in the lower minor allele frequency (MAF) spectrum of our
data, variants with MAF < 0.01 cannot be reliably included in these
GWAS analyses. Future GWAS studies employing rare-variant
imputation or large-scale sequencing efforts may potentially pro-
vide more insight into shared heritability in the rare variant spec-
trum. Third, phenotypic heterogeneity in ALS and epilepsy might
result in a dilutionof signal of possible sharedgenetic underpinnings.
Althoughwe have tested genetic correlationswith epilepsy subtypes
(focal and generalized), a detailed characterization of both ALS and
epilepsypatients could identify subgroups that share phenotypic and
pathological characteristics that might share a genetic basis. How-
ever, at present such phenotypic information is unavailable at suffi-
ciently large sample sizes for cross-disorder analyses.Disclosure statement
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